Kezar Life Sciences, Inc. (KZR): Price and Financial Metrics


Kezar Life Sciences, Inc. (KZR)

Today's Latest Price: $5.36 USD

0.38 (-6.62%)

Updated Oct 28 10:36am

Add KZR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

KZR Stock Price Chart Interactive Chart >

Price chart for KZR

KZR Price/Volume Stats

Current price $5.36 52-week high $9.79
Prev. close $5.74 52-week low $2.18
Day low $5.33 Volume 29,245
Day high $5.70 Avg. volume 431,281
50-day MA $5.03 Dividend yield N/A
200-day MA $4.76 Market Cap 247.93M

Kezar Life Sciences, Inc. (KZR) Company Bio


Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.


KZR Latest News Stream


Event/Time News Detail
Loading, please wait...

KZR Latest Social Stream


Loading social stream, please wait...

View Full KZR Social Stream

Latest KZR News From Around the Web

Below are the latest news stories about Kezar Life Sciences Inc that investors may wish to consider to help them evaluate KZR as an investment opportunity.

Encouraging lupus data lifts Kezar Life Sciences, up 9% after hours

Kezar Life Sciences (KZR) is up 9% after hours in reaction to data from the Phase 1b portion of the Phase 1/2 MISSION study evaluating lead candidate KZR-616 in patients with systemic lupus erythematosus ((SLE)) and lupus nephritis ((LN)). The results were presented virtually at the Pan-American Congress on Rheumatology.As of May...

Seeking Alpha | September 17, 2020

Kezar Highlights Data from MISSION Phase 1b Study of KZR-616 during the Pan American Congress of Rheumatology

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today highlighted data from the Phase 1b portion of the MISSION study demonstrating safety, tolerability and early efficacy signals of KZR-616 in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) at the Pan-American Congress of Rheumatology (PANLAR 2020

Business Wire | September 17, 2020

Kezar Life Sciences (KZR) Investor Presentation - Slideshow

The following slide deck was published by Kezar Life Sciences, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 11, 2020

Kezar Life Sciences to Participate in Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of the executive team will present during upcoming virtual investor conferences. The details of the presentations are as follows: Wells Fargo 2020 Virtual Biotech Conference Fireside Chat: Thursday, September 10, 2020, 1:20pm EDT Presenter

Business Wire | September 3, 2020

Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update

SAN FRANCISCO--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its second quarter 2020 financial results and corporate highlights. “Our excitement continues to build around the novel mechanism of KZR-616 and supports our conviction that targeting master regulators of cellular function – like the immunoproteasome – can benefit patients i

Business Wire | August 5, 2020

Read More 'KZR' Stories Here

KZR Price Returns

1-mo 16.27%
3-mo 21.54%
6-mo 17.54%
1-year 54.47%
3-year N/A
5-year N/A
YTD 33.67%
2019 -83.01%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6798 seconds.